Compare SMFG & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMFG | GSK |
|---|---|---|
| Founded | 2002 | 1715 |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.3B | 96.1B |
| IPO Year | N/A | N/A |
| Metric | SMFG | GSK |
|---|---|---|
| Price | $19.53 | $53.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2M | ★ 4.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 2.30% | ★ 3.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.22 | $6.81 |
| Revenue Next Year | $7.58 | $4.74 |
| P/E Ratio | ★ $30.92 | $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.96 | $32.38 |
| 52 Week High | $24.34 | $61.70 |
| Indicator | SMFG | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 39.47 |
| Support Level | $19.29 | $47.89 |
| Resistance Level | $19.57 | $60.37 |
| Average True Range (ATR) | 0.48 | 0.95 |
| MACD | -0.33 | -0.73 |
| Stochastic Oscillator | 12.74 | 5.77 |
Sumitomo Mitsui Financial Group is roughly tied with Mizuho Financial Group for the status of Japan's second-largest bank after Mitsubishi UFJ Financial Group. As of March 2025, its market share of domestic loans was 7.3%, compared with 8.4% for MUFG. It has a larger consumer finance business than the other two megabanks, owning 100% of the Promise business and SMBC Card. It also controls one of Japan's largest leasing companies and SMBC Aviation Capital, one of the top five aircraft lessors globally. In securities, its SMBC Nikko unit is Japan's third-largest retail broker, although SMFG has lagged somewhat in institutional securities business and asset management.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.